New Antibiotic Drug Combo AIDS TB Therapy
Posted on: Wednesday, 19 September 2007, 15:00 CDT
U.S. and Brazilian scientists have developed a new antibiotic drug combination that has been found effective in treating tuberculosis.
The team of tuberculosis experts at Johns Hopkins University and the Federal University of Rio de Janeiro discovered substituting the antibiotic moxifloxacin in the regimen of drugs used to treat the highly contagious form of lung disease could shorten the time needed to cure the illness from six to four months.
The researchers found adding moxifloxacin to a standard combination of other antibiotics increased by 17 percent the number of patients who cleared active infections from their lungs -- raising cure rates from 68 percent to 85 percent -- after just two months of therapy, and when compared to patients taking the standard combination with another, older antibiotic, ethambutol.
This is the most compelling evidence in nearly 25 years that a novel antibiotic drug combination works better than the current gold standard at curing active TB infection, said study senior author Dr. Richard Chaisson.
The findings were presented Wednesday in Chicago during the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Source: United Press International
Related Articles
- ROTATEQ(R) Substantially Reduced Rotavirus-Related Hospitalizations and Emergency Room Visits Combined in New U.S. Observational Study
- SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined With Standard of Care Chemotherapy
- Romark Completes Enrollment in Phase II Hepatitis Combination Therapy Study
- Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination With Standard Chemotherapy
- Valopicitabine Combined With Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
- New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined With Standard of Care Chemotherapy
- OncoGenex Lung-Cancer Drug Shines in Study
- Energy Metals Corporation and Quincy Energy Corp. Enter into Merger Agreement; Energy Metals Corporation Completes Business Combination With Standard Uranium Inc.
- New Data Demonstrate ZEVALIN(R) Radioimmunotherapy May Play Greater Role in Combination With Standard of Care for Various Types of Lymphoma
- Millennium Initiates Combination Phase I/II Trial of MLN518 in Acute Myelogenous Leukemia
 |
 |
User Comments (0)
RSS Feeds